The mission of Virginia Commonwealth University School of Engineering’s Medicines for All Institute (M4ALL) is to transform pharmaceutical manufacturing to reduce medication cost and improve patient access. M4ALL has a demonstrated ability to apply new chemical processes and technology to identify cost savings across all three areas that drive inflated drug costs (i.e., starting materials, API, and batch versus continuous process manufacturing) and thus reduce patient access to life-saving medications. Full scale up of M4ALL will result in significant savings in the cost of essential global health medications. These cost savings will reduce the cost burden on global health organizations and permit more patients to receive more treatment, even in a resource-constrained environment. In addition, these cost savings will reduce barriers to introduction of otherwise higher costs new and improved treatments.
While M4ALL possesses deep expertise in pharmaceutical manufacturing, they sought advice on engaging with funders and other key stakeholders to secure grant funding and sponsored projects.
The Arcady Group has engaged with M4ALL to advise in the following areas:
- Development of a business plan for M4ALL, presentations and related materials to describe M4ALL activities and value proposition, and strategies to secure both grant and fee income for M4ALL activities,
- Activities related to solicitation of fee-based work from generic and other “for profit” manufacturers for the services and output of M4ALL, thus providing the sustainable funding base essential to secure grant funding and to grow the facilities, resources, offerings and impact of M4ALL, and
- Subject matter expertise and contacts within TB and HIV, including members of the Gates Foundation TB-PST and also representatives of Stop TB Partnership, Global Drug Facility, TB Reach, TB Alliance, UNITAID, USAID, and Global Fund
Based in part on these efforts, M4ALL is exceptionally well positioned to scale-up as planned and to comprehensively and positively impact patient access to existing and new and improved global health treatments.